Alliance Audit Regulatory Review

Kurombi Wade-Oliver, BA, CCRP
Alliance Chicago Office

November 3, 2016

Presentation Objectives

- Identify the Regulatory Review Process and the Documents that will be reviewed

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Presentation Objectives

- Identify the Regulatory Review Process and the Documents that will be reviewed
  - Prior to the audit
    - Protocols approved through the utilization of a local IRB
    - Protocols approved through the utilization of the CIRB

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Presentation Objectives

- Identify the Regulatory Review Process and the Documents that will be reviewed
  - Prior to the audit
    - Protocols approved through the utilization of a local IRB
    - Protocols approved through the utilization of the CIRB
  - During the audit
    - Protocols approved through the utilization of local IRB
    - Protocols approved through the utilization of the CIRB

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Presentation Objectives

- Identify the Regulatory Review Process and the Documents that will be reviewed
  - Prior to the audit
    - Protocols approved through the utilization of a local IRB
    - Protocols approved through the utilization of the CIRB
  - During the audit
    - Protocols approved through the utilization of local IRB
    - Protocols approved through the utilization of the CIRB
- Describe Common Regulatory Deficiencies found during an audit

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Presentation Objectives

- Identify the Regulatory Review Process and the Documents that will be reviewed
  - Prior to the audit
    - Protocols approved through the utilization of a local IRB
    - Protocols approved through the utilization of the CIRB
  - During the audit
    - Protocols approved through the utilization of local IRB
    - Protocols approved through the utilization of the CIRB
- Describe Common Regulatory Deficiencies found during an audit
- How to Avoid Regulatory Deficiencies

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Regulatory Review

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Regulatory Review

- Regulatory review is the review of the foundation documents for conducting a particular study at your site.

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Regulatory Review

- Regulatory review is the review of the foundation documents for conducting a particular study at your site.
  - Two Step Process
    - Pre-review
    - At time of audit

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Regulatory Review

- Regulatory review is the review of the foundation documents for conducting a particular study at your site.
  - Two Step Process
    - Pre-review
    - At time of audit
  - Two Parts
    - IRB review
    - Informed Consent Content Review

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review

- Per CTMB guidelines section 4.1, the list of protocols and patient cases selected will be supplied to the site at least 2 weeks (no more than 4) prior to the audit

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review

- For each protocol selected for audit the site will forward the following regulatory documents to the Chicago Office prior to the audit date

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review

- For each protocol selected for audit the site will forward the following regulatory documents to the Chicago Office prior to the audit date
  - Initial (Final) IRB Protocol Approval
  - Continuing / Annual Renewal Approvals
  - Required Amendment / Update Approvals
  - Selected Locally Utilized Informed Consent Form
  - Applicable Corresponding Model Consent

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review

- For each protocol selected for audit the site will forward the following regulatory documents to the Chicago Office prior to the audit date
  - Trials reviewed under the CIRB
    - Approval letter from CIRB noting local IRB acceptance
    - Study specific worksheet with local context
    - Selected locally utilized informed consent form
    - Applicable corresponding model consent
  - All other CIRB approval documents will be reviewed at the time of audit

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review
Part I: IRB Review



ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review
Part I: IRB Review

What are Auditors looking for?

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review
Part I: IRB Review

What are Auditors looking for?

- Documentation of IRB Approval

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review
Part I: IRB Review

What are Auditors looking for?

- Documentation of IRB Approval
- IRB Review Type

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review
Part I: IRB Review

What are Auditors looking for?

- Documentation of IRB Approval
- IRB Review Type
- Timing

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Initial IRB Protocol Approval

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Initial IRB Protocol Approval

What are we looking for?

July 1, 2014

Project Number:	Alliance A011106
Project Title:	ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Sponsor:	Alliance for Clinical Trials in Oncology
Primary Investigator:	
Meeting Date:	5/22/2014
IRB Approval Date:	6/26/2014
IRB Expiration Date:	5/21/2015
Type of Approval:	Full Committee Review

Dear Investigator:

This is to certify that your research proposal involving human subject participants has been reviewed and **approved** by the IRB. This approval is based upon the assurance that you will protect the rights and welfare of the research participants, employ approved methods of securing informed consent from these individuals, and not involve undue risk to the human subjects in light of potential benefits that can be derived from participation.

Approval of this research is contingent upon your agreement to:

(1) Adhere to all Policies and Procedures Relating to Human Subjects, as written in accordance with the Code of Federal Regulations (45 CFR 46).

(2) Maintain copies of all pertinent information related to the research study including, but not limited to, video and audio tapes, instruments, copies of written informed consent agreements, and any other supportive documents in accordance with the Research Records Retention Policy.

(3) Report potentially serious events to IRB by completing the "Adverse Event Report".

(4) Submit deviations from previously approved research activities which were immediately necessary to eliminate apparent and immediate dangers to the subjects.

(5) Submit Amendments to the IRB for any proposed changes from the previously approved project. Changes may not be initiated without prior IRB review and approval.

(6) Submit an Application for Continuing Review to the IRB before the expiration date. Federal regulations and policies require continuing review of research at intervals appropriate to the degree of risk, but not less than once per year.

If you have any questions regarding the human subject protection process, please do not hesitate to contact our office.

Very truly yours,

IRB Coordinator

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Initial IRB Protocol Approval

What are we looking for?

- Approval date and signature by the Chair (or designee)



July 1, 2014

Project Number: Alliance A011106
Project Title: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Sponsor: Alliance for Clinical Trials in Oncology
Primary Investigator:
Meeting Date: 5/22/2014
IRB Approval Date: 6/26/2014
IRB Expiration Date: 5/21/2015
Type of Approval: Full Committee Review

Dear Investigator:

This is to certify that your research proposal involving human subject participants has been reviewed and **approved** by the IRB. This approval is based upon the assurance that you will protect the rights and welfare of the research participants, employ approved methods of securing informed consent from these individuals, and not involve undue risk to the human subjects in light of potential benefits that can be derived from participation.

Approval of this research is contingent upon your agreement to:

(1) Adhere to all Policies and Procedures Relating to Human Subjects, as written in accordance with the Code of Federal Regulations (45 CFR 46).
(2) Maintain copies of all pertinent information related to the research study including, but not limited to, video and audio tapes, instruments, copies of written informed consent agreements, and any other supportive documents in accordance with the Research Records Retention Policy.
(3) Report potentially serious events to IRB by completing the "Adverse Event Report".
(4) Submit deviations from previously approved research activities which were immediately necessary to eliminate apparent and immediate dangers to the subjects.
(5) Submit Amendments to the IRB for any proposed changes from the previously approved project. Changes may not be initiated without prior IRB review and approval.
(6) Submit an Application for Continuing Review to the IRB before the expiration date. Federal regulations and policies require continuing review of research at intervals appropriate to the degree of risk, but not less than once per year.

If you have any questions regarding the human subject protection process, please do not hesitate to contact our office.

Very truly yours,

IRB Coordinator

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Initial IRB Protocol Approval

What are we looking for?

- Approval date and signature by the Chair (or designee)
- Full Board Review



July 1, 2014

Project Number: Alliance A011106
Project Title: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Sponsor: Alliance for Clinical Trials in Oncology
Primary Investigator:
Meeting Date: 5/22/2014
IRB Approval Date: 6/26/2014
IRB Expiration Date: 5/21/2015
Type of Approval: Full Committee Review

Dear Investigator:

This is to certify that your research proposal involving human subject participants has been reviewed and approved by the IRB. This approval is based upon the assurance that you will protect the rights and welfare of the research participants, employ approved methods of securing informed consent from these individuals, and not involve undue risk to the human subjects in light of potential benefits that can be derived from participation.

Approval of this research is contingent upon your agreement to:

(1) Adhere to all Policies and Procedures Relating to Human Subjects, as written in accordance with the Code of Federal Regulations (45 CFR 46).
(2) Maintain copies of all pertinent information related to the research study including, but not limited to, video and audio tapes, instruments, copies of written informed consent agreements, and any other supportive documents in accordance with the Research Records Retention Policy.
(3) Report potentially serious events to IRB by completing the "Adverse Event Report".
(4) Submit deviations from previously approved research activities which were immediately necessary to eliminate apparent and immediate dangers to the subjects.
(5) Submit Amendments to the IRB for any proposed changes from the previously approved project. Changes may not be initiated without prior IRB review and approval.
(6) Submit an Application for Continuing Review to the IRB before the expiration date. Federal regulations and policies require continuing review of research at intervals appropriate to the degree of risk, but not less than once per year.

If you have any questions regarding the human subject protection process, please do not hesitate to contact our office.

Very truly yours,

IRB Coordinator

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Initial IRB Protocol Approval

What are we looking for?

- Approval date and signature by the Chair (or designee)
- Full Board Review
- Approval was received prior to patient enrollment

July 1, 2014

Project Number: Alliance A011106
Project Title: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Sponsor: Alliance for Clinical Trials in Oncology
Primary Investigator:
Meeting Date: 5/22/2014
IRB Approval Date: 6/26/2014
IRB Expiration Date: 5/21/2015
Type of Approval: Full Committee Review

Dear Investigator:

This is to certify that your research proposal involving human subject participants has been reviewed and approved by the IRB. This approval is based upon the assurance that you will protect the rights and welfare of the research participants, employ approved methods of securing informed consent from these individuals, and not involve undue risk to the human subjects in light of potential benefits that can be derived from participation.

Approval of this research is contingent upon your agreement to:

(1) Adhere to all Policies and Procedures Relating to Human Subjects, as written in accordance with the Code of Federal Regulations (45 CFR 46).
(2) Maintain copies of all pertinent information related to the research study including, but not limited to, video and audio tapes, instruments, copies of written informed consent agreements, and any other supportive documents in accordance with the Research Records Retention Policy.
(3) Report potentially serious events to IRB by completing the "Adverse Event Report".
(4) Submit deviations from previously approved research activities which were immediately necessary to eliminate apparent and immediate dangers to the subjects.
(5) Submit Amendments to the IRB for any proposed changes from the previously approved project. Changes may not be initiated without prior IRB review and approval.
(6) Submit an Application for Continuing Review to the IRB before the expiration date. Federal regulations and policies require continuing review of research at intervals appropriate to the degree of risk, but not less than once per year.

If you have any questions regarding the human subject protection process, please do not hesitate to contact our office.

Very truly yours,

IRB Coordinator

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Continuing / Annual Reviews

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Continuing / Annual Reviews

What are we looking for?

DATE: April 20, 2015

TO: M.D.
FROM: Institutional Review Board

STUDY TITLE: [564237-3] A041202 - A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

IRB REFERENCE #:
SUBMISSION TYPE: Continuing Review/Progress Report

ACTION: APPROVED
APPROVAL DATE: April 2, 2015
EXPIRATION DATE: April 1, 2016
REVIEW TYPE: Full Board

- Continuing Review - IRB Submission Form
- Consent Form, Update 1, Dated 6/1/14 - (Addition of Physician Name - Submitting consent for renewal stamp)
- HIPAA Consent/Authorization (Only submitting for renewal stamp)
- Alliance Data and Safety Monitoring Board (DSMB) Report Dated 12/23/14

Thank you for your submission of the items as listed for the above research study. Institutional Review Board has approved the items as submitted at its regularly scheduled meeting.

Please remember that informed consent is a process beginning with a description of the study and insurance of participant understanding followed by a signed consent form. Informed consent must continue throughout the study via a dialogue between the researcher and research participant. Federal regulations require each participant receive a copy of the signed consent document.

Please note that any revision to previously approved materials must be approved by this office prior to initiation. Please use the appropriate revision forms for this procedure.

All SERIOUS and UNEXPECTED adverse events must be reported to this office. Please use the appropriate adverse event forms for this procedure. All FDA and sponsor reporting requirements should also be followed.

Please report all NON-COMPLIANCE issues or COMPLAINTS regarding this study to this office.

Please note that all research records must be retained for a minimum of three years.

Based on the risks, this project requires Continuing Review by this office on an annual basis. Please use the appropriate renewal forms for this procedure.

If you have any questions, please contact or Please include your study title and reference number in all correspondence with this office.

Chairperson

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Continuing / Annual Reviews

What are we looking for?

- Approval is ≤ 365 days from last review/initial approval



DATE: April 20, 2015

TO: M.D.
FROM: Institutional Review Board

STUDY TITLE: [564237-3] A041202 - A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

IRB REFERENCE #:
SUBMISSION TYPE: Continuing Review/Progress Report

ACTION: APPROVED
APPROVAL DATE: April 2, 2015
EXPIRATION DATE: April 1, 2016
REVIEW TYPE: Full Board

- Continuing Review - IRB Submission Form
- Consent Form, Update 1, Dated 6/1/14 - (Addition of Physician Name - Submitting consent for renewal stamp)
- HIPAA Consent/Authorization (Only submitting for renewal stamp)
- Alliance Data and Safety Monitoring Board (DSMB) Report Dated 12/23/14

Thank you for your submission of the items as listed for the above research study. Institutional Review Board has approved the items as submitted at its regularly scheduled meeting.

Please remember that informed consent is a process beginning with a description of the study and insurance of participant understanding followed by a signed consent form. Informed consent must continue throughout the study via a dialogue between the researcher and research participant. Federal regulations require each participant receive a copy of the signed consent document.

Please note that any revision to previously approved materials must be approved by this office prior to initiation. Please use the appropriate revision forms for this procedure.

All SERIOUS and UNEXPECTED adverse events must be reported to this office. Please use the appropriate adverse event forms for this procedure. All FDA and sponsor reporting requirements should also be followed.

Please report all NON-COMPLIANCE issues or COMPLAINTS regarding this study to this office.

Please note that all research records must be retained for a minimum of three years.

Based on the risks, this project requires Continuing Review by this office on an annual basis. Please use the appropriate renewal forms for this procedure.

If you have any questions, please contact or Please include your study title and reference number in all correspondence with this office.

Chairperson

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Continuing / Annual Reviews

What are we looking for?

- Approval is ≤ 365 days from last review/initial approval
- Full board reviewed for protocols w/ active recruitment or subjects on active treatment



DATE: April 20, 2015

TO: M.D.
FROM: Institutional Review Board

STUDY TITLE: [564237-3] A041202 - A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

IRB REFERENCE #:
SUBMISSION TYPE: Continuing Review/Progress Report

ACTION: APPROVED
APPROVAL DATE: April 2, 2015
EXPIRATION DATE: April 1, 2016
REVIEW TYPE: Full Board

- Continuing Review - IRB Submission Form
- Consent Form, Update 1, Dated 6/1/14 - (Addition of Physician Name - Submitting consent for renewal stamp)
- HIPAA Consent/Authorization (Only submitting for renewal stamp)
- Alliance Data and Safety Monitoring Board (DSMB) Report Dated 12/23/14

Thank you for your submission of the items as listed for the above research study. Institutional Review Board has approved the items as submitted at its regularly scheduled meeting.

Please remember that informed consent is a process beginning with a description of the study and insurance of participant understanding followed by a signed consent form. Informed consent must continue throughout the study via a dialogue between the researcher and research participant. Federal regulations require each participant receive a copy of the signed consent document.

Please note that any revision to previously approved materials must be approved by this office prior to initiation. Please use the appropriate revision forms for this procedure.

All SERIOUS and UNEXPECTED adverse events must be reported to this office. Please use the appropriate adverse event forms for this procedure. All FDA and sponsor reporting requirements should also be followed.

Please report all NON-COMPLIANCE issues or COMPLAINTS regarding this study to this office.

Please note that all research records must be retained for a minimum of three years.

Based on the risks, this project requires Continuing Review by this office on an annual basis. Please use the appropriate renewal forms for this procedure.

If you have any questions, please contact or Please include your study title and reference number in all correspondence with this office.

Chairperson

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

What are we looking for?

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

What are we looking for?

- Approvals are obtained within 90 days of the group's notification date
  - Alliance broadcasts occur on the 1st and 15th of the month
  - CTSU broadcasts occur on the 8th and 22nd of the month

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

What are we looking for?

- Approvals are obtained within 90 days of the group's notification date
  - Alliance broadcasts occur on the 1st and 15th of the month
  - CTSU broadcasts occur on the 8th and 22nd of the month
- The IRB review is appropriate to the requirement (i.e. full board vs. expedited)

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

Protocol Update #06
03/25/2015

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

PROTOCOL UPDATE TO ALLIANCE A021202

PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB (NSC # 737754, IND 75648) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS

Pazopanib and matching placebo will be supplied by GlaxoSmithKline and distributed by CTEP

[X] **Update:**	[ ] **Status Change:**
[ ] Eligibility changes	[ ] Activation
[ ] Therapy / Dose Modifications / Study Calendar changes	[ ] Closure
[X] Informed Consent changes	[ ] Suspension / temporary closure
[ ] Scientific / Statistical Considerations changes	[ ] Reactivation
[ ] Data Submission / Forms changes	
[ ] Editorial / Administrative changes	
[X] Other : Updated CAEPR	

The changes included in this update to A021202 have been made in response to the NCI Action Letter from Dr. Pamela Harris dated March 24, 2015. This Action Letter is posted on the A021202 Study Page on the Alliance web site. A revised CAEPR with the new risk has been added to the protocol. Therefore, the model consent form has been revised to incorporate this new risk consistent with the new NCI Model Template Instructions.

IRB approval (or disapproval) of this update is required within 90 days. Full Board review is recommended. Please follow your IRB of record's policies.

No new patients may be consented onto this protocol until IRB approval for this amendment has been obtained. Patients consented on or before March 25, 2015 may be enrolled onto this trial before local IRB approval of the revised protocol and informed consent form has been obtained.

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

Protocol Update #06
03/25/2015

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

PROTOCOL UPDATE TO ALLIANCE A021202

PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB (NSC # 737754, IND 75648) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS

Pazopanib and matching placebo will be supplied by GlaxoSmithKline and distributed by CTEP

[X]	**Update:**	[ ]	**Status Change:**
[ ]	Eligibility changes	[ ]	Activation
[ ]	Therapy / Dose Modifications / Study Calendar changes	[ ]	Closure
[X]	Informed Consent changes	[ ]	Suspension / temporary closure
[ ]	Scientific / Statistical Considerations changes	[ ]	Reactivation
[ ]	Data Submission / Forms changes		
[ ]	Editorial / Administrative changes		
[X]	Other : Updated CAEPR		

The changes included in this update to A021202 have been made in response to the NCI Action Letter from Dr. Pamela Harris dated March 24, 2015. This Action Letter is posted on the A021202 Study Page on the Alliance web site. A revised CAEPR with the new risk has been added to the protocol. Therefore, the model consent form has been revised to incorporate this new risk consistent with the new NCI Model Template Instructions.

IRB approval (or disapproval) of this update is required within 90 days. Full Board review is recommended. Please follow your IRB of record's policies.

No new patients may be consented onto this protocol until IRB approval for this amendment has been obtained. Patients consented on or before March 25, 2015 may be enrolled onto this trial before local IRB approval of the revised protocol and informed consent form has been obtained.

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part I: IRB Review

Required Amendments / Updates

Protocol Update #06
03/25/2015

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

PROTOCOL UPDATE TO ALLIANCE A021202

PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB (NSC # 737754, IND 75648) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS

Pazopanib and matching placebo will be supplied by GlaxoSmithKline and distributed by CTEP

[X]	**Update:**	[ ]	**Status Change:**
[ ]	Eligibility changes	[ ]	Activation
[ ]	Therapy / Dose Modifications / Study Calendar changes	[ ]	Closure
[X]	Informed Consent changes	[ ]	Suspension / temporary closure
[ ]	Scientific / Statistical Considerations changes	[ ]	Reactivation
[ ]	Data Submission / Forms changes		
[ ]	Editorial / Administrative changes		
[X]	Other : Updated CAEPR		

The changes included in this update to A021202 have been made in response to the NCI Action Letter from Dr. Pamela Harris dated March 24, 2015. This Action Letter is posted on the A021202 Study Page on the Alliance web site. A revised CAEPR with the new risk has been added to the protocol. Therefore, the model consent form has been revised to incorporate this new risk consistent with the new NCI Model Template Instructions.

IRB approval (or disapproval) of this update is required within 90 days. Full Board review is recommended. Please follow your IRB of record's policies.

No new patients may be consented onto this protocol until IRB approval for this amendment has been obtained. Patients consented on or before March 25, 2015 may be enrolled onto this trial before local IRB approval of the revised protocol and informed consent form has been obtained.

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Common IRB Major Deficiencies

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Common IRB Major Deficiencies

IRB Review (Table A)

	IRB Deficiency Descriptions
Major	Protocol never approved by IRB
	Initial IRB approval documentation missing
	Initial approval by expedited review
	Expedited reapproval for situations other than approved exceptions
	Registration and/or treatment of patient prior to full IRB approval
	Reapproval delayed greater than 30 days but less than one year
	Registration of patient on protocol during a period of delayed reapproval or during a temporary suspension (ie, Request for Rapid Amendment)
	Missing reapproval
	Expired reapproval
	Internal reportable adverse events reported late or not reported to the IRB
	Lack of documentation of IRB approval of a protocol amendment that affects more than minimal risk or IRB approval is greater than 90 days after Network Group's notification; this includes a 'Request for Rapid Amendment (RRA)' resulting from an Action Letter indicating temporary suspension of accrual with expedited review permitted
	Failure to submit or submitted after 90 days, any reportable external safety report to the IRB that is considered an unanticipated problem as defined by OHRP
Lesser	Protocol reapproval delayed 30 days or less
	Delayed reapproval for protocol closed to accrual for which all patients/study participants have completed therapy

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Common IRB Major Deficiencies

A study was submitted to the IRB for continuing review that would expire on 11/6/15. On 11/2/15 the site received contingent approval. The IRB required study clarifications and ICC changes. The study received full continuing review approval on12/15/15.

IRB Review (Table A)

	IRB Deficiency Descriptions
Major	Protocol never approved by IRB
	Initial IRB approval documentation missing
	Initial approval by expedited review
	Expedited reapproval for situations other than approved exceptions
	Registration and/or treatment of patient prior to full IRB approval
	Reapproval delayed greater than 30 days but less than one year
	Registration of patient on protocol during a period of delayed reapproval or during a temporary suspension (ie, Request for Rapid Amendment)
	Missing reapproval
	Expired reapproval
	Internal reportable adverse events reported late or not reported to the IRB
	Lack of documentation of IRB approval of a protocol amendment that affects more than minimal risk or IRB approval is greater than 90 days after Network Group's notification; this includes a 'Request for Rapid Amendment (RRA)' resulting from an Action Letter indicating temporary suspension of accrual with expedited review permitted
	Failure to submit or submitted after 90 days, any reportable external safety report to the IRB that is considered an unanticipated problem as defined by OHRP
Lesser	Protocol reapproval delayed 30 days or less
	Delayed reapproval for protocol closed to accrual for which all patients/study participants have completed therapy

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Common IRB Major Deficiencies

Update 6, broadcast on 6/15/16, was submitted to the IRB. A review of documents revealed the site over looked the submission of update 5, broadcast on 3/15/16. The site informed the IRB. The IRB acknowledged since the changes for update 5 were incorporated in update 6, therefore update 5 was approved with update 6 on 7/26/16.

IRB Review (Table A)

	IRB Deficiency Descriptions
Major	Protocol never approved by IRB
	Initial IRB approval documentation missing
	Initial approval by expedited review
	Expedited reapproval for situations other than approved exceptions
	Registration and/or treatment of patient prior to full IRB approval
	Reapproval delayed greater than 30 days but less than one year
	Registration of patient on protocol during a period of delayed reapproval or during a temporary suspension (ie, Request for Rapid Amendment)
	Missing reapproval
	Expired reapproval
	Internal reportable adverse events reported late or not reported to the IRB
	Lack of documentation of IRB approval of a protocol amendment that affects more than minimal risk or IRB approval is greater than 90 days after Network Group's notification; this includes a 'Request for Rapid Amendment (RRA)' resulting from an Action Letter indicating temporary suspension of accrual with expedited review permitted
	Failure to submit or submitted after 90 days, any reportable external safety report to the IRB that is considered an unanticipated problem as defined by OHRP
Lesser	Protocol reapproval delayed 30 days or less
	Delayed reapproval for protocol closed to accrual for which all patients/study participants have completed therapy

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Common IRB Major Deficiencies

- Amendment approvals obtained **greater than 90 days** post group's notification
- Continuing review approved by **expedited review** when full board review is needed
- Expired continuing reviews **greater than 30 days** late

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step I: Regulatory Pre-Review
Part II: Informed Consent Content

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part II: Informed Consent Content

- A minimum of 3 consents will be selected for review
- For each consent selected the site will forward the following to the Chicago Office prior to the audit date (including CIRB reviewed studies)
  - Current approved locally utilized informed consent form
  - Applicable model consent

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part II: Informed Consent Content

ALLIANCE MODEL CONSENT FORM:

RANDOMIZED PHASE II STUDY COMPARING CABOZANTINIB (NSC #761968 AND IND #116059) WITH COMMERCIALLY SUPPLIED SUNITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

This is a clinical trial, a type of research study. Your study doctor will explain the clinical trial to you. Clinical trials include only people who choose to take part. Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

You are being asked to take part in this study because you have advanced or metastatic kidney cancer

Why is this study being done?

The purpose of this study is to find out what effects, good and/or bad, two study drugs called sunitinib and cabozantinib have on you and on advanced or metastatic kidney cancer. Sunitinib has been approved by the FDA and cabozantinib is an investigational drug. Both medications target special proteins that are on the surface of the kidney cancer cell and both drugs are taken by mouth.

How many people will take part in the study?

About 150 people will take part in this study.

Site Name/Logo Here

Consent Form

Title of Protocol

Randomized Phase II Study Comparing Cabozantinib (NSC#761968 and IND#116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.

Who is conducting this study?

Principal Investigator:

Sub-Investigators:

Sponsor: Alliance for Clinical Trials in Oncology (Alliance)

This is a clinical trial, a type of research study. Your study doctor will explain the clinical trial to you. Clinical trials include only people who choose to take part. Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

Why have I been asked to take part in this research study?

You have been asked to take part in this study because you have advanced or metastatic kidney cancer.

Why is this study being conducted?

The purpose of this study is to find out what effects, good and/or bad, two study drugs called sunitinib and cabozantinib have on you and on advanced or metastatic kidney cancer. Sunitinib has been approved by the FDA and cabozantinib is an investigational drug. Both medications

Part II: Informed Consent Content

- Informed Consent Forms are reviewed for the 8 basic required elements of a consent (21CFR50.25)
  - Study involves research
  - Description of foreseeable risks
  - Description of benefits
  - Disclosure of alternatives
  - Description describing confidentiality maintenance
  - Compensation / treatment in the case of injury
  - Contact information for questions regarding research/rights
  - Participation is voluntary

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part II: Informed Consent Content

- Informed Consent Forms are reviewed for additional elements (21CFR50.25)
  - Treatment may involve risks
  - Anticipated circumstances in which subject's participation may be terminated
  - Additional costs to the subject
  - Consequences for subject's decision to withdraw
  - Subject will be informed of significant new findings
  - Approximate number of subjects
  - A copy of this form will be given to the subject
  - http://www.ClinicalTrials.gov website listed per U.S. law

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Part II: Informed Consent Content

CIRB Trials

Yes the informed consent form is reviewed!

Because CIRB is the **IRB of record** your locally utilized consent must be a **word for word** match with the model consent with the exception of what is approved **by the CIRB** on the study specific worksheet with local context

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Informed Consent Content Common Major Deficiencies

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Informed Consent Content Common Major Deficiencies

Informed Consent Content (ICC) Review
(Table B)

	ICC Deficiency Descriptions
Required Elements per the Federal Regulations	Involves research: purposes; duration of participation; description of procedures; identification of experimental procedures
	Description of risks or discomforts
	Description of any benefits to subject or others
	Disclosure of alternative procedures or treatments
	Description of the extent of confidentiality of records
	Explanation regarding compensation and/or whether treatments are available if injury occurs
	Was there an explanation of whom to contact for answers to pertinent questions about the research and research subject's rights, and whom to contact in the event of a research related injury to the subject?
	Participation is voluntary; refusal to participate involves no penalty; subject may discontinue participation at any time
	Unforeseeable risks to subject, embryo or fetus
	Circumstances in which subject's participation may be terminated by investigator without subject's consent
	Additional costs to subject which may result from participation in research
	Consequences of subject withdrawal and procedures for orderly termination of participation by subject
	Statement that new findings which may relate to subject's willingness to continue participation will be provided to subject
	Disclosure of approximate number of participants
	Statement stating: "A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time."
	Statement that a copy of the consent will be given to study participant

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Informed Consent Content Common Major Deficiencies

On an Alliance trial studying the effect of using Olanzapine in patients currently on chemotherapy experiencing nausea/vomiting. When reviewing the site's ICF, we noted the addition of the risk "Weight gain which may cause diabetes" which was not found in the model consent.

Informed Consent Content (ICC) Review
(Table B)

	ICC Deficiency Descriptions
Required Elements per the Federal Regulations	Involves research: purposes; duration of participation; description of procedures; identification of experimental procedures
	Description of risks or discomforts
	Description of any benefits to subject or others
	Disclosure of alternative procedures or treatments
	Description of the extent of confidentiality of records
	Explanation regarding compensation and/or whether treatments are available if injury occurs
	Was there an explanation of whom to contact for answers to pertinent questions about the research and research subject's rights, and whom to contact in the event of a research related injury to the subject?
	Participation is voluntary; refusal to participate involves no penalty; subject may discontinue participation at any time
	Unforeseeable risks to subject, embryo or fetus
	Circumstances in which subject's participation may be terminated by investigator without subject's consent
	Additional costs to subject which may result from participation in research
	Consequences of subject withdrawal and procedures for orderly termination of participation by subject
	Statement that new findings which may relate to subject's willingness to continue participation will be provided to subject
	Disclosure of approximate number of participants
	Statement stating: "A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by U.S. Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time."
	Statement that a copy of the consent will be given to study participant

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Informed Consent Content Common Major Deficiencies

- **Omission** of one or more risks
- **Omission** of one or more of the required informed consent elements
- **Changes** to the following without Alliance approval
  - Additions to the risks
  - Additions / Omissions to the list of alternative options
  - Changes to the translational research section (including the questions)

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step II: Regulatory Review at Time of Audit

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step II: Regulatory Review at Time of Audit

- Review of regulatory approval documents for any unannounced protocols

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step II: Regulatory Review at Time of Audit

- Review of regulatory approval documents for any unannounced protocols
- Review submission of unanticipated / IND reports per your IRB policy

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step II: Regulatory Review at Time of Audit

- Review of regulatory approval documents for any unannounced protocols
- Review submission of unanticipated / IND reports per your IRB policy
- CIRB reviewed trials
  - Ensure all CIRB regulatory approvals are on file at your site
    - Continuing / Annual review approvals
    - All required amendment / update approvals
    - Review of any approvals from the local IRB prior to CIRB review acceptance (if applicable)

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Step II: Regulatory Review at Time of Audit

- Resolve any regulatory and consent discrepancies found during the pre-review / time of audit
- Assess any regulatory findings

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid Regulatory Deficiencies

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid IRB Deficiencies

Get Organized!

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid IRB Deficiencies

Get Organized!

- Create a separate chronological regulatory file for each protocol and each document type
  - Initial Final Approval
  - Continuing Reviews
  - Required Amendments

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid IRB Deficiencies

Get Organized!

- Create a separate chronological regulatory file for each protocol and each document type
  - Initial Final Approval
  - Continuing Reviews
  - Required Amendments
- Print, Flag and File approval documents ASAP!

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid IRB Deficiencies

Get Organized!

- Create a separate chronological regulatory file for each protocol and each document type
  - Initial Final Approval
  - Continuing Reviews
  - Required Amendments
- Print, Flag and File approval documents ASAP!
- Create a calendar for tracking regulatory deadlines
  - Deadlines for protocol submissions to IRB
  - Reminders to check email/sponsor website on broadcast dates

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid ICC Deficiencies

- Utilize the model consent as your local informed consent form!
  - Copy the model **word for word**
  - Insert local language where appropriate
  - Have a double check system of review

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid ICC Deficiencies

- Utilize the model consent as your local informed consent form!
  - Copy the model **word for word**
  - Insert local language where appropriate
  - Have a double check system of review
- The content of certain ICC sections should **NEVER** change
  - Risk List
  - Alternative procedures / treatment
  - Translational research section (wording/order of the questions)

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

How to Avoid ICC Deficiencies

- Contact the **Alliance** for approval for ICC changes
  - Risk List
  - Alternative procedures / treatment
  - Translational research section
  - Changes that may alter the intent/methodology of the study

- See **Alliance** Policy & Procedure section 2.8.7.2.2

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Conclusion: Regulatory Review

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Conclusion: Regulatory Review

- Regulatory review is a two step process
  - Pre-review (prior to the audit date)
  - Items reviewed at the time of the audit

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Conclusion: Regulatory Review

- Regulatory review is a two step process
  - Pre-review (prior to the audit date)
  - Items reviewed at the time of the audit
- Regulatory review occurs in two parts
  - IRB review
  - Informed Consent Content review

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Conclusion: Regulatory Review

- Regulatory review is a two step process
  - Pre-review (prior to the audit date)
  - Items reviewed at the time of the audit
- Regulatory review occurs in two parts
  - IRB review
  - Informed Consent Content review
- Common Major Deficiencies
  - IRB review
  - Informed Consent Content review
  - How to Avoid Deficiencies

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

Website Resources

The Alliance for Clinical Trials in Oncology

www.allianceforclinicaltrialsinoncology.org

FDA Code of Federal Regulations

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm

Cancer Therapy Evaluation Program (CTEP)

http://ctep.cancer.gov/branches/ctmb/clinicalTrials/docs/ctmb_audit_guidelines.pdf

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY


THANK YOU!
Questions from Audience
Answers from Presenter